Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | QPCT | Q16769 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578652 | 0.88 | QPCT (0.32) | IDH1NOTUMMAOBQPCTHSD11B1 | |
| SCHEMBL3575078 | 0.86 | NOTUM (0.35) | IDH1NOTUMQPCTOPRM1HSD11B1 | |
| SCHEMBL3580768 | 0.85 | ALDH1A1 (0.31) | NOTUMMAOB | |
| SCHEMBL3580713 | 0.84 | MAOB (0.36) | IDH1MAOB | |
| SCHEMBL3573182 | 0.81 | NOTUM (0.31) | NOTUM | |
| SCHEMBL3578214 | 0.80 | MAPK1 (0.40) | IDH1NOTUMQPCTOPRM1HSD11B1 | |
| SCHEMBL7814733 | 0.79 | ALDH1A1 (0.41) | IDH1NOTUMQPCT | |
| SCHEMBL7823338 | 0.79 | NOTUM (0.40) | IDH1NOTUMQPCT | |
| SCHEMBL3573031 | 0.78 | METAP2 (0.32) | IDH1OPRM1SLC6A9SLC6A5METAP2 | |
| SCHEMBL3586944 | 0.78 | ALDH1A1 (0.33) | NOTUMQPCTOPRM1SLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729269-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2014-05-20 | — | — | US | disclosed |
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7687627-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2010-03-30 | — | — | US | disclosed |
| EP-1664038-A2 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY | Wockhardt Limited (IN) | 2006-06-07 | — | — | EP | disclosed |
| US-20050143421-A1 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED | 2005-06-30 | — | — | US | disclosed |
| WO-2005054234-A2 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED (IN) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | GMPS, MPO, ARG1 | IDH1 4505/4885NOTUM 2823/4885MAOB 2975/4885 |
| US-20050143421-A1 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | GMPS, MPO, ARG1 | IDH1 4505/4885NOTUM 2823/4885MAOB 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.